How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,586 results for

Uterine Fibroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Systematic Review and Meta-analysis of Comparisons between HIFU and Conventional Therapies for Uterine Fibroids

Systematic Review and Meta-analysis of Comparisons between HIFU and Conventional Therapies for Uterine Fibroids Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

122. Clinical Efficacy of Acupuncture Combined with Traditional Chinese Medicine for Uterine Fibroids: A Systematic Review and Meta-Analysis

Clinical Efficacy of Acupuncture Combined with Traditional Chinese Medicine for Uterine Fibroids: A Systematic Review and Meta-Analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

123. Efficacy assessment of Fire Needle in the treatment of Uterine Fibroids: a systematic review and meta-analysis

Efficacy assessment of Fire Needle in the treatment of Uterine Fibroids: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

124. Chinese herbal medicine Tripterygium wilfordii Hook F for treating uterine fibroids: a systematic review and meta-analysis of randomized controlled trials

Chinese herbal medicine Tripterygium wilfordii Hook F for treating uterine fibroids: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

125. Effectiveness comparisons of Fire Needle for Uterine Fibroids: a systematic review and meta-analysis

Effectiveness comparisons of Fire Needle for Uterine Fibroids: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

126. EMA guidance on use of Esmya for fibroids does not change FSRH recommendations regarding use of ulipristal acetate for emergency contraception

EMA guidance on use of Esmya for fibroids does not change FSRH recommendations regarding use of ulipristal acetate for emergency contraception FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids - Faculty of Sexual and Reproductive Healthcare FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids FSRH CEU response to European Medicines (...) Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids Share this article e7fea81d68b496a675766672fde9c22e Published on: 12 February 2018 File size: 225kb PDF File type: Clinical Statements The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review

2018 Faculty of Sexual & Reproductive Healthcare

127. Uterine artery embolization versus surgical treatment in patients with symptomatic uterine fibroids: a systematic review and meta-analysis of individual participant data

Uterine artery embolization versus surgical treatment in patients with symptomatic uterine fibroids: a systematic review and meta-analysis of individual participant data Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2018 PROSPERO

128. Different dosages of mifepristone versus enantone to treat uterine fibroids: A multicenter randomized controlled trial. Full Text available with Trip Pro

Different dosages of mifepristone versus enantone to treat uterine fibroids: A multicenter randomized controlled trial. To evaluate the efficacy and safety of 10 mg and 25 mg mifepristone per day compared with 3.75 mg enantone in treating uterine fibroids.This is a Multicenter randomized controlled trial. A total of 501 subjects with symptomatic uterine fibroids were enrolled and randomized into the group of 10mg, 25mg mifepristone and 3.75 enantone (with 307, 102 and 92 subjects respectively (...) ), with 458 subjects completed the treatment. Three months of daily therapy with oral mifepristone (at a dose of either 10 mg or 25 mg) or once-monthly subcutaneous injections of enantone (at a dose of 3.75 mg) were used. Change in volume of the largest uterine fibroid was the primary efficacy variable, and secondary efficacy variables included changes in anemia and relevant symptom. Safety evaluation included the analyses of adverse events, laboratory values, and relevant endometrial changes.After three

2017 Medicine Controlled trial quality: uncertain

129. Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2017 Clinical Trials

130. Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment of Heavy (...) Menstrual Bleeding in Women With Uterine Fibroids The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03317795 Recruitment Status : Recruiting First Posted : October 23, 2017 Last Update Posted : January 14, 2019 See Sponsor

2017 Clinical Trials

131. Uterine fibroids – what’s new? Full Text available with Trip Pro

Uterine fibroids – what’s new? Uterine fibroids are the commonest benign tumours of women and affect all races with a cumulative lifetime risk of around 70%. Despite their high prevalence and the heavy economic burden of treatment, fibroids have received remarkably little attention compared to common female malignant tumours. This article reviews recent progress in understanding the biological nature of fibroids, their life cycle and their molecular genetic origins. Recent progress

2017 F1000Research

132. Treating symptomatic uterine fibroids with myomectomy: current practice and views of UK consultants Full Text available with Trip Pro

Treating symptomatic uterine fibroids with myomectomy: current practice and views of UK consultants 29285023 2018 11 13 1613-2076 14 1 2017 Gynecological surgery Gynecol Surg Treating symptomatic uterine fibroids with myomectomy: current practice and views of UK consultants. 28 10.1186/s10397-017-1033-1 Mallick R R 0000-0001-7516-9132 Department of Gynaecology, Barts Health NHS Trust, Whipps Cross University Hospital, London, E11 1NR UK. grid.439471.c Odejinmi F F Department of Gynaecology

2017 Gynecological surgery

133. 3D Power Doppler vascular indices as a novel technique in assessing the outcome of minimally invasive techniques in uterine fibroids treatment Full Text available with Trip Pro

3D Power Doppler vascular indices as a novel technique in assessing the outcome of minimally invasive techniques in uterine fibroids treatment Uterine fibroids are considered to be the most frequent female benign tumours. The most common reported symptoms of fibroids are heavy menstrual bleeding and painful menstruation, pelvic pain, urinary problems, constipation, as well as infertility and recurrent pregnancy loss. The mainstay of fibroid treatment is surgery, but nowadays minimally-invasive (...) techniques are growing in popularity. Vascularity of fibroids may play a role in the outcome of these techniques, which is why it is important to find an objective, reproducible technique to measure the vascularization before and after the procedure. The 3D Power Doppler vascular indices (3DPDVI) allow objective assessment of vascularization in the entire volume of the tumour. Initially this technique was mostly used in experimental imaging phantoms, but recently many studies focus on the clinical

2017 PrzeglaÌœd menopauzalny = Menopause review

134. Minimally invasive procedures in the management of uterine fibroids Full Text available with Trip Pro

Minimally invasive procedures in the management of uterine fibroids Uterine fibroids are benign uterine tumors. In women during the reproductive period, uterine fibroids occur in about 25%, whereas after this time, they are observed in more than 40% of women. In the majority of women (about 20-50%), such tumors do not cause discomfort and do not require treatment. Asymptomatic uterine fibroids usually undergo only regular medical control, whereas symptomatic fibroids are an indication (...) , but still experimental. The use of MRgFUS/MR-HIFU for the thermoablative treatment of fibroids was approved by the FDA (Food and Drug Administration) in 2004. As a minimally invasive method, it enables preservation of the uterus and eliminates the need for general anesthesia. LUAO is based on the use of the vascular clip, which is placed on the uterine artery at the level of the internal iliac artery. This procedure is performed bilaterally. The use of UAE in obstetrics and gynecology was first

2017 PrzeglaÌœd menopauzalny = Menopause review

135. Fertility impairment associated with uterine fibroids – a review of literature Full Text available with Trip Pro

Fertility impairment associated with uterine fibroids – a review of literature Uterine fibroids (also known as leiomyomas or myomas) are the most common benign tumors affecting reproductive organs in women. They are monoclonal tumors of the uterine smooth muscle, which spring from myometrium. It is estimated that they occur in 50-60% of the female population and rise to 70% by the age of 50. While mostly asymptomatic, myomas can be connected with several conditions, including abnormal (...) bleeding with subsequent anemia, pelvic masses, pelvic pain, bulk symptoms, unfavorable impact on fertility and obstetric complications. Factors, which predispose the emergence of fibroids are: hormones, Afro-American ethnicity, age, obesity, adverse pregnancy outcome history, early menarche, genetic factors, alcohol, caffeine or eating too much red meat. On the other hand, there are factors, which can decrease this risk: pregnancy, early menopause and tobacco smoking. There are several mechanisms

2017 PrzeglaÌœd menopauzalny = Menopause review

136. Ulipristal acetate as a treatment option for uterine fibroids Full Text available with Trip Pro

Ulipristal acetate as a treatment option for uterine fibroids Uterine fibroids are the most common benign uterine tumours. Clinical symptoms include abnormal bleeding, pelvic pressure, pelvic pain, infertility and obstetric complications. Approximately one third of women with fibroids will require treatment. The management also depends on the number, size, and location of the fibroids. There are surgical and non-surgical treatment options. The choice of therapy depends on different factors (...) , such as the severity of symptoms, tumour characteristics, age, and wish to preserve the uterus and fertility. There is growing evidence of the main role of progesterone pathways in the pathophysiology of uterine fibroids due to the use of selective progesterone receptor modulators such as ulipristal acetate. The efficacy of long-term intermittent use of UPA was recently demonstrated by randomised controlled studies. There is great demand for alternatives to surgical intervention, especially in women seeking

2017 PrzeglaÌœd menopauzalny = Menopause review

137. Combining situ-morcellation with continuous-fill-mattress suture in laparoscopic myomectomy: A surgical approach of choice for patients with large uterine fibroids. Full Text available with Trip Pro

Combining situ-morcellation with continuous-fill-mattress suture in laparoscopic myomectomy: A surgical approach of choice for patients with large uterine fibroids. To investigate the efficacy and advantage of combining situ-morcellation with continuous-fill-mattress suture compared with conventional morcellation and suture in laparoscopic myomectomy.One hundred sixteen patients who underwent laparoscopic myomectomy from March 2014 to October 2016.Patients were divided into combining situ

2017 Medicine

138. Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. (Abstract)

Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. Uterine fibroids (UF) are associated with significant health-related quality of life (HRQL) impact. This study examined the impact of UF symptoms on HRQL.An online cross-sectional survey of 18 to 49 year old US women was conducted and collected demographics, UF prevalence, symptoms, and HRQL using the UFS-QOL. Descriptive statistics were used to examine the impact of symptom

2017 Current medical research and opinion

139. Focus on Uterine Fibroids: Evolving Options to Optimize Care. (Abstract)

Focus on Uterine Fibroids: Evolving Options to Optimize Care. 28866121 2018 01 26 2018 01 26 1097-6868 217 5 2017 11 American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Focus on uterine fibroids: evolving options to optimize care. 626 S0002-9378(17)30966-3 10.1016/j.ajog.2017.08.019 Singh Sukhbir Sony SS Associate Professor and Vice-Chair of Gynecology, Department of Obstetrics and Gynecology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada. Marsh Erica E EE (...) Associate Professor and Chief, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan Health System University of Michigan, Ann Arbor, Michigan. eng Journal Article Research Support, Non-U.S. Gov't 2017 09 01 United States Am J Obstet Gynecol 0370476 0002-9378 AIM IM Female Humans Leiomyoma diagnosis therapy Uterine Neoplasms diagnosis therapy 2017 9 4 6 0 2018 1 27 6 0 2017 9 4 6 0 ppublish 28866121 S0002-9378(17)30966-3 10.1016/j.ajog

2017 American Journal of Obstetrics and Gynecology

140. Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. Full Text available with Trip Pro

Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. To assess the changes in antimüllerian hormone (AMH) levels after ablation for symptomatic uterine fibroids and adenomyosis using ultrasound-guided high-intensity focused ultrasound (USgHIFU).A prospective study.Gynaecological department in multiple hospitals in South Korea.Patients with uterus fibroids (...) and adenomyosis.Seventy-nine women with symptomatic uterine fibroids and adenomyosis who met the inclusion criteria were enrolled in our study between January 2014 and December 2014. All patients underwent USgHIFU ablations. Each patient was examined before and after treatment, and at 6 and 12 months after treatment by T2-weighted MRI imaging (T2WI) and T1-weighted MRI imaging (T1WI) with gadolinium injection. Symptom severity scores (SSS), Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire subscales

2017 BJOG

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>